Wednesday, February 10, 2016| , Glaucoma, , Myopia,

EyewireTV — Glaucoma Progression Contact Lens; Childhood Myopia On The Rise

In this week’s EyewireTV, a new study shows that the Sensimed Triggerfish contact lens system may help determine which glaucoma patients have a higher risk of disease progression; and in what researchers are calling the largest study of childhood eye diseases ever undertaken in the United States, the USC Eye Institute reports a significant increase in childhood myopia. Also, Oculus receives 510(k) clearance from the FDA for the Pentacam AXL anterior segment tomography device. (1612 Views)

Watch Video

Wednesday, February 03, 2016

EyewireTV - Vegetables and Glaucoma?... InnFocus MicroShunt 3-Year Data

In this week’s EyewireTV, a study reveals that greater intake of dietary nitrate and green leafy vegetables is associated with a lower risk for primary open-angle glaucoma; and new data shows that glaucoma patients treated with the InnFocus MicroShunt Drainage System and followed for over 3 years experienced a significant reduction in both IOP and use of glaucoma medication. In the feature, three leading ophthalmologists discuss how they are currently utilizing health apps to improve practice efficiency, and which apps they are recommending to patients. (2780 Views)

Watch Video

Wednesday, January 27, 2016

EyewireTV - Alcon Restructuring; Lifitegrast NDA Resubmission

In this week’s EyewireTV, Novartis announces a major restructuring of its Alcon unit in an attempt to return its eye care business to growth by the end of the year; and a new international study shows use of the Glaukos iStent in conjunction with cataract surgery provides IOP reduction and reduces glaucoma medications 3 years following surgery. Also, Shire resubmits a new drug application to the FDA for its dry eye drug candidate, lifitegrast. (4272 Views)

Watch Video

Wednesday, January 20, 2016

EyewireTV - Refractive Lens-Based Surgery Subspecialty?

In this week’s EyewireTV, with rising patient expectations and emerging technology in the refractive surgery market, international ophthalmologists discuss whether they believe refractive lens-based surgery should be its own subspecialty, and whether a subset of surgeons should limit themselves exclusively to refractive cataract surgery. (2656 Views)

Watch Video

Wednesday, January 13, 2016

EyewireTV - Shire Buys Baxalta; Lee Nordan is Remembered

In this week’s EyewireTV, in a major deal that will create the world’s biggest rare-disease drugmaker, Shire agrees to combine with Baxalta in a deal valued at about $32 billion; and ophthalmology industry veteran Tom Frinzi is named senior vice president, Abbott, and will be responsible for heading the company's vision business, Abbott Medical Optics. Also, colleagues pay tribute to internationally acclaimed refractive surgeon Lee Nordan, MD, who recently passed away at the age of 69. (3238 Views)

Watch Video

Wednesday, January 06, 2016

EyewireTV - New Cross-Linking Device; Ophthalmic Executive Changes

In this week’s EyewireTV, Avedro receives CE Mark clearance for its Mosaic cross-linking system, which has the potential for nonsurgical improvement for patients with low myopia; and a new study shows that dry eye disease does not necessarily worsen over time, although those with a history of severe symptoms were more likely to experience worsening. Also, a series of executive changes in the ophthalmic space are announced. (2706 Views)

Watch Video

Wednesday, December 30, 2015

EyewireTV - 2015 Year in Review

A look back at some of EyewireTV’s most significant stories from 2015. It was another active year in ophthalmology, marked by significant mergers and acquisitions, FLACS upgrades, the introduction of new postoperative eye drop formulations, new indications for well-known retina agents, and the first FDA approval of a corneal inlay. The year also included the health sector’s largest acquisition ever with Pfizer and Allergan agreeing to merge in a $160 billion deal. (3004 Views)

Watch Video

Wednesday, December 23, 2015

EyewireTV - Multiple iStents Study; New PASCAL Laser

In this week's EyewireTV, a new international study shows the potential for titratable treatment with multiple iStents in glaucoma patients; and Topcon Medical Systems releases a new version of its PASCAL Synthesis pattern scanning laser. Also, the FDA has accepted for review Ocular Therapeutix’s new drug application for Dextenza for the treatment of postoperative ocular pain. (3174 Views)

Watch Video

Wednesday, December 16, 2015

EyewireTV - Ophthalmic Executives Provide Company Updates

In this week's EyewireTV, several executives at the Ophthalmology Innovation Summit in Las Vegas speak to EyewireTV about the main product candidates in their companies' pipelines. (3366 Views)

Watch Video

Wednesday, December 09, 2015

EyewireTV - Allergan CEO Brent Saunders Speaks About Future of Allergan’s Eye Care After Pfizer Merger

In this week’s EyewireTV, Allergan President and CEO Brent Saunders speaks about what the proposed merger with Pfizer means for the company’s eye care business; and Merck exits ophthalmology after selling its remaining glaucoma products to Singapore-based Mundipharma. Also, Clearside Biomedical announces that the first patient was enrolled in the company’s phase 3 clinical trial for its treatment candidate for macular edema associated with non-infectious uveitis. (3486 Views)

Watch Video

Wednesday, December 02, 2015

EyewireTV - Dextenza Phase 3 Trial; Ophthalmologists Laser Vision Study

In this week’s EyewireTV, enrollment begins in a second phase 3 clinical trial evaluating the safety and efficacy of Ocular Therapeutix’s Dextenza (sustained-release dexamethasone 0.4 mg intracanalicular depot) for the treatment of allergic conjunctivitis; and a new study reveals that ophthalmologists who perform laser vision correction are significantly more likely than the general population to have laser refractive surgery in their own eyes. Also, an analysis of patients from the FAME study demonstrates a significant slowing of the progression of diabetic retinopathy in patients with diabetic macular edema treated with Alimera Sciences' Iluvien. (2410 Views)

Watch Video

Tuesday, November 24, 2015

EyewireTV - Pfizer — Allergan Merger; Breaking News from AAO (Part 2)

In this week’s EyewireTV, Pfizer and Allergan enter into a definitive agreement to combine in a deal worth about $160 billion – the biggest deal ever in the pharmaceutical industry; and Carl Zeiss Meditec introduces the IOL Master 700 with swept-source biometry to the US market. Also, Leica Microsystems launches the Proveo 8 ophthalmic microscope platform for cataract and vitreoretinal surgeries. (3374 Views)

Watch Video
Load More